Capricor Therapeutics Inc. (CAPR) shares went up 7.28% in after-hours on Wednesday, June 23, 2021, and closed the day at $5.60 per share. Earlier in the morning, CAPR’s stock lost 8.74% to close Wednesday’s session at $5.22. CAPR shares have risen 8.52% over the last 12 months, and they have moved up by 18.64% in the past week. Over the past three months, the stock has gained 5.45%, while over the past six months, it has declined 30.50%.
Presentation of Phase II HOPE-2 trial study
Capricor Therapeutics CEO, Linda Marbán, Ph.D., was set to provide an update on recent findings after a preliminary review of the Company’s ongoing open-label extension study of Phase II HOPE-2 trial with a lead asset, CAP-1002, at the Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference. The event was scheduled for Wednesday, June 23, from 6:41 to 7:40 p.m. ET.
Participation in recent BIO Digital 2021 conference
Capricor Therapeutics recently participated in BIO Digital 2021 conference which held on June 10-11 and June 14-18, 2021. The company had discussions with investors and potential partners at the conference.
Preclinical Data presentation ofExosome-mRNA Vaccine
Capricor Therapeutics presented supporting preclinical data for its Exosome-Mediated mRNA Delivery approach against SARS-CoV-2 at the 10th Annual Meeting of the International Society for Extracellular Vesicles (ISEV), which held virtually on May 18-21, 2021.
Recent financial results announcement
OnMay 13, 2021, Capricor Therapeutics released its financial results for the first quarter ended March 31, 2021,
Q1 2021 financial highlights
- The company reported total revenue of $40,816 thousand for Q1 2021 compared to $185,693 thousand for Q1 2020.
- Capricor Therapeuticssuffered a net loss of approximately $5.2 million, or $0.23 per share in Q1 2021 compared to a net loss of approximately $2.1 million, or $0.30 per share, for the first quarter of 2020.
- Total operating expenses were $5.2 million compared to $2.23 million in Q1 2020.
- The company cash and cash equivalents totaled approximately $41.9 million on March 31, 2021, compared to approximately $32.7 million on December 31, 2020.
Participation at ASGCT24th annual meeting
Capricor Therapeutics participated at the American Society of Gene and Cell Therapy’s (ASGCT) 24th annual meeting, which held virtually on May 11-14, 2021. The company was presented by Capricor’s CEO Linda Marbán, Ph.D.
Worldwide License Agreement with Johns Hopkins University
On April 29, 2021, Capricor Therapeutics signed an exclusive, worldwide licensing agreement with Johns Hopkins University (JHU) to include engineered exosomes for vaccines and therapeutics as part of the Company’s exosome technology portfolio.
Well, we can assume that the Phase II HOPE-2 trial study results presentation could be the reason behind CAPR stock’s positive performance in the after-hours on Wednesday. The CAPR share price can further climb in the coming days.